Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
NCT ID: NCT04592445
Last Updated: 2022-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2020-12-18
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endovascular GSN Ablation in Subjects With HFpEF
NCT04287946
Low Voltage-Directed Catheter Ablation for Atrial Fibrillation
NCT03355456
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)
NCT06703489
Baroreflex Sensitivity in Patients Undergoing Ablation of Atrial Fibrillation
NCT04503122
Effect of taVNS on Heart Rate in Persistent Atrial Fibrillation
NCT05944575
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects who meet the eligibility criteria and are enrolled will be randomized 1:1 to either ablation of the right GSN using the Axon System (treatment cohort) or sham (control cohort) at the time of the procedure.
This study will enroll up to 100 subjects at an anticipated 20 US sites. Subject follow up is at 1, 3, 6, and 12 months
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Axon Treatment Arm
Subjects will receive treatment with the Satera Ablation System following administration of anesthesia access to the R GSN and ablation of the GSN at 1-2 levels will occur.
Satera GSN Ablation
The Axon procedure consists of a small needle puncture made in the groin to pass standard sheaths, wires, and access devices into the femoral vein, using standard access methods. The right GSN will be ablated transvenously from the right intercostal veins where it crosses at the 10th and 11th thoracic vertebrae from the intercostal vein intersection with the azygos vein. Placement of the access devices and Axon catheter is confirmed using standard fluoroscopic imaging. Once positioning is confirmed, GSN ablation can commence accordingly .
Sham Control Arm
Following administration of anesthesia subjects will have femoral vein access only. Procedure choreography to mimic procedure steps and length.
Sham Control
The sham procedure consists of a small needle puncture made in the groin to pass a standard femoral introducer sheath approximately 10 cm into the femoral vein, using standard access methods. The Axon Catheter and associated access accessories will not be inserted into the patient. The sham procedure duration will be similar to the treatment time for subject receiving the Axon therapy (\~30 minutes).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Satera GSN Ablation
The Axon procedure consists of a small needle puncture made in the groin to pass standard sheaths, wires, and access devices into the femoral vein, using standard access methods. The right GSN will be ablated transvenously from the right intercostal veins where it crosses at the 10th and 11th thoracic vertebrae from the intercostal vein intersection with the azygos vein. Placement of the access devices and Axon catheter is confirmed using standard fluoroscopic imaging. Once positioning is confirmed, GSN ablation can commence accordingly .
Sham Control
The sham procedure consists of a small needle puncture made in the groin to pass a standard femoral introducer sheath approximately 10 cm into the femoral vein, using standard access methods. The Axon Catheter and associated access accessories will not be inserted into the patient. The sham procedure duration will be similar to the treatment time for subject receiving the Axon therapy (\~30 minutes).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Chronic heart failure defined as at least one of the following:
1. Symptoms of HF requiring current treatment with diuretics (intermittent or continuous) for \> 30 days, AND
2. NYHA class II with a history of \> NYHA class II in the past year, NYHA class III, or ambulatory NYHA class IV symptoms (paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate exertion) at screening; or signs of HF (any rales post cough, chest x-ray demonstrating pulmonary congestion), AND
3. \> 1 HF hospital admission (with HF as the primary, or secondary diagnosis);
* OR - treatment with intravenous (IV) diuretics, or intensification of oral diuresis for HF in a healthcare facility within the 12 months prior to study entry;
* OR - NT-pro BNP value \> 150 pg/ml in normal sinus rhythm, \> 450 pg/ml in atrial fibrillation within the past 6 months;
* OR - BNP value \> 50 pg/ml in normal sinus rhythm, \> 150 pg/ml in atrial fibrillation within the past 6 months.
3. Ongoing stable GDMT HF management (unless unable to tolerate GDMT) and management of potential comorbidities according to the 2017 ACCF/AHA Guideline for the Management of Heart Failure, with no significant changes \[\>100% increase or 50% decrease\] for a minimum of 1 month prior to screening, that is expected to be maintained without change for at least 3 months.
4. LVEF ≥ 50 % (site determined by TTE) in the past 3 months.
5. Site determined elevated PCWP documented by right heart catheterization by PCWP ≥ 25 mmHg during supine ergometer exercise
a. PCWP to be evaluated by a Swan Ganz procedure performed either prior to the day of the index procedure or on the day of the index procedure
6. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.
Exclusion Criteria
2. Cardiac Resynchronization Therapy initiated within the past 3 months prior to screening.
3. Advanced heart failure defined as one or more of the below:
1. ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF
2. Cardiac index \< 2.0 L/min/m2
3. Inotropic infusion (continuous or intermittent) for LV EF\< 30% within the past 6 months prior to screening
4. Subject is on the cardiac transplant waiting list
4. BMI \> 45 kg/m2
5. Inability to perform 6-minute walk test (distance \< 100 meters), OR ability to perform 6-minute walk test distance \> 450 meters.
6. Admission for HF within the 30 days prior to planned index procedure.
7. In the last 3 years an ejection fraction (EF) below 40
8. Systolic BP \< 100 mmHg or \> 170 mmHg despite appropriate medical management.
9. Symptomatic orthostatic hypotension or orthostatic hypotension requiring treatment (orthostatic hypotension is defined as systolic blood pressure decrease of \>20mmHg and/or increase in heart rate \>20 bpm upon going from supine to standing position).
10. Arterial oxygen saturation \< 90 % on room air.
11. Presence of significant valve disease defined by the site cardiologist as:
1. Mitral valve stenosis defined as \<1.5 cm2 (or greater than mild)
2. Mitral valve regurgitation defined as grade \> 3+ MR
3. Tricuspid valve regurgitation defined as grade \> 3+ TR
4. Aortic valve disease defined as \> 3+ AR or \> severe AS
12. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or other infiltrative cardiomyopathy (e.g., hemochromatosis, sarcoidosis)
13. Vessel tortuosity or variant vascular anatomy that could preclude the access or maneuvering of the interventional device from the access site to target vessel. This includes previous spine surgery that may impact the ability to access and treat the target sites of T11 and T10.
14. Mean resting right atrial pressure (RAP) \> 20 mmHg based upon screening right heart catheterization.
15. History of severe liver cirrhosis
16. Dialysis dependent; or estimated-GFR \<25 ml/min/1.73 m2 by MDRD equation.
17. Baseline status of persistent atrial fibrillation with resting HR \>100 beats per minute that could obfuscate RHC interpretation.
18. Chronic pulmonary disease requiring continuous home oxygen OR hospitalization for exacerbation (including intubations) in the 12 months before study entry OR known history of GOLD Class II or higher COPD.
19. Currently participating in conflicting investigational drug or device study.
20. Life expectancy \<12 months for non-cardiovascular reasons.
21. Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient.
22. Females who are not pregnant or lactating and not or planning to become pregnant for the duration of the study during the next year.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Axon Therapies, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology PC
Birmingham, Alabama, United States
Arizona Cardiovascular Research Center
Phoenix, Arizona, United States
Scripps Health
La Jolla, California, United States
University of California, San Francisco
San Francisco, California, United States
Bluhm Cardiovascular Institute of Northwestern University
Chicago, Illinois, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Prairie Education and Research Cooperative
Springfield, Illinois, United States
Cardiovascular Institute of the South
Houma, Louisiana, United States
Michigan Medicine, University of Michigan
Ann Arbor, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Weill Cornell Medicine
New York, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Center for Advanced Cardiac Care, Columbia University Medical Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Medical University of South Carolina, Gazes Cardiac Research Institute
Charleston, South Carolina, United States
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Fudim M, Borlaug BA, Mohan RC, Price MJ, Fail P, Goyal P, Hummel SL, Zirakashvili T, Shaburishvili T, Patel RB, Reddy VY, Nielsen CD, Chetcuti SJ, Sukul D, Gulati R, Kim L, Benzuly K, Mitter SS, Klein L, Uriel N, Augostini RS, Blair JE, Rocha-Singh K, Burkhoff D, Patel MR, Somo SI, Litwin SE, Shah SJ. Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical Trial. JAMA Cardiol. 2024 Dec 1;9(12):1143-1153. doi: 10.1001/jamacardio.2024.2612.
Fudim M, Litwin SE, Borlaug BA, Mohan RC, Price MJ, Fail P, Zirakashvili T, Shaburishvili T, Goyal P, Hummel SL, Patel RB, Reddy VY, Burkhoff D, Patel MR, Somo SI, Shah SJ. Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: Rationale, Design and Lead-in Phase Results of the REBALANCE-HF Trial. J Card Fail. 2024 Jul;30(7):877-889. doi: 10.1016/j.cardfail.2023.12.010. Epub 2024 Jan 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09868
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.